COMPARE · Data as of August 21, 2026
NMR vs XP
Verdict: Side-by-side breakdown using the Bull Rankings model. NMR scored 69.0, XP scored 74.0 — XP leads.
Compare another set
NMR
Nomura Holdings, Inc.
69Fin
$9.72 · $28.4B
Strength gap
0.8
XP leads
XP
XP Inc.
69.8Fin
$16.81 · $8.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestXP8.6x
- Fastest growthNMR+10.8%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
Fundamentals, head-to-head
NMR
XP
+10.8%B
Rev
+7.3%B
11.6xB+
P/E
8.6xA-
11.2%B
ROE
22.6%A-
1.15B+
P/B
1.76B
3.4%B
Yield
1.2%C+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
NMRNomura Holdings, Inc.
Why now
Capital Markets · market cap $28.4b. 3% off the 52-week high of $10.06. Revenue growing +11%, comfortably above the S&P median. PEG 0.81 — paying under fair value for the growth rate.
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Financial moat — scale of deposit base / underwriting franchise plus regulatory capital advantages. The largest players compound book value through cycles that erase smaller competitors.
Risk
D/E 9.46 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
XPXP Inc.
Why now
Capital Markets · market cap $8.5b. Down 27% from 52-week high of $23.13 — deep drawdown territory. PEG 0.59 — paying under fair value for the growth rate. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $21.98 (implying +31% upside).
Moat
Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Financial moat — scale of deposit base / underwriting franchise plus regulatory capital advantages. The largest players compound book value through cycles that erase smaller competitors.
Risk
D/E 6.42 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.